Abstract:Abstract Background Nitric oxide/cGMP/CREB signaling is critical for learning and memory processes and is disturbed by Abeta amyoid and in Alzheimer’s disease. AR1001 is an inhibitor of phosphodiesterase (PDE)‐5, which degrades specifically cGMP, thus having a potential to reverse AD pathology. Method For the in vivo study, AR1001 was intraperitoneally administered (4 mg/kg/day) to APP‐C105 mice for 4 weeks. Then after behavioral tests (Morris‐water maze and passive avoidance tests) were done, hippocampal levels of Abeta1‐42 and p‐Tau (S199/202) were determined. In the in vitro study using human neuroblastoma SH‐SY5Y cells and mouse hippocampal HT‐22 cells, the effects of AR1001 on Abeta1‐42‐induced cytotoxicity and intracellular signaling were examined. Result AR1001 markedly improved cognitive functions in both Morris‐water maze and passive avoidance tests and reduced hippocampal Abeta1‐42 and p‐Tau levels in the APP‐C105 mice. In the in vitro experiments, AR1001 inhibited Abeta1‐42‐induced cell death, mitochondrial membrane potential derangement, and apoptotic markers (cleaved caspase‐3 and cleaved PPAR) concentration‐dependently. AR1001 reversed Abeta1‐42‐induced decrease in phosphorylated CREB (p‐CREB), and NGF/BDNF expression. Further, AR1001 blocked Abeta1‐42‐induced p Ser9 ‐GSK3beta decrease and p25/p35 increase. Interestingly, compared with sildenafil, vardenafil and tadalafil, AR1001 was more effective in inhibiting glucocorticoid receptor (GR) dimerization and Wnt antagonist Dickkopf‐1 (Dkk‐1) expression, and in enhancing Wnt3a expression. Conclusion AR1001 had protective effects both in vivo and in vitro models of AD. Furthermore, AR1001 showed more pronounced activity in the modulation of GR and Wnt signaling among the various PDE‐5 inhibitors. It is suggested that the multimodal activity of AR1001 contributes to the therapeutic effects of AR1001 observed in the phase 2 clinical trial in AD patients (NCT03625622).

GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects

Ganoderma Lucidum Triterpenoids (glts) Reduce Neuronal Apoptosis Via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice

Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury

GV1001 Inhibits the Severity of the Ligature-Induced Periodontitis and the Vascular Lipid Deposition Associated with the Periodontitis in Mice

γ-Glutamyl-Transpeptidase-Resistant Glutathione Analog Attenuates Progression of Alzheimer’s Disease-like Pathology and Neurodegeneration in a Mouse Model

hTERT Peptide Fragment GV1001 Prevents the Development of Porphyromonas gingivalis-Induced Periodontal Disease and Systemic Disorders in ApoE-Deficient Mice

γ-Glutamylcysteine ameliorates D-gal-induced senescence in PC12 cells and mice via activating AMPK and SIRT1.

Long-Term Administration of Triterpenoids From Ganoderma lucidum Mitigates Age-Associated Brain Physiological Decline via Regulating Sphingolipid Metabolism and Enhancing Autophagy in Mice

Vitegnoside Mitigates Neuronal Injury, Mitochondrial Apoptosis, and Inflammation in an Alzheimer's Disease Cell Model via the p38 MAPK/JNK Pathway

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Geroprotective effects of Alzheimer's disease drug candidates

Gastrodiae rhizoma attenuates brain aging via promoting neuritogenesis and neurodifferentiation

Utilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging

NXP032 ameliorates cognitive impairment by alleviating the neurovascular aging process in aged mouse brain

Tetrahydroxystilbene Glucoside Delayed Senile Symptoms in Old Mice via Regulation of the AMPK/SIRT1/PGC-1α Signaling Cascade

NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid-β and Restores Synaptic Structures in APP/PS1 Transgenic Mice

Protective Effects of AR1001 in Alzheimer’s Disease Models: Polypharmacological Mechanisms

A Benzenesulfonamide GW8510 Rejuvenates Mice and Yeast Through Interaction with P21-Activated Kinases

New intranasal and injectable gene therapy for healthy life extension

Protective effects of GTM-1 on endoplasmic reticulum stress induced by thapsgargin in rat neurons.

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease